Egetis Therapeutics Investor Relations Material
Latest events
Investor Day 2023
Egetis Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Egetis Therapeutics
Access all reports
Egetis Therapeutics develops and markets drugs for the treatment of rare and serious diseases in the orphan drug segment. Its main drug candidates currently include Aladote, a drug that reduces the risk of acute liver injury associated with acetaminophen/paracetamol poisoning and is being developed in phase IIb/III clinical trials; and Emcitate, a drug for the treatment of MCT8 deficiency (a rare inborn error of thyroid hormone signaling).
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇸🇪 Sweden